Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | PDE9A | O76083 | 11/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9006277 | 0.93 | SRC (0.45) | CYP3A4SRCPDE9AFLT3PIK3CD | |
| Trifluoroacetic Acid SCHEMBL4367371 | 0.85 | CYP3A4 (0.54) | CYP3A4PDE9AFLT3CYP2C9 | |
| SCHEMBL4328580 | 0.85 | CYP3A4 (0.51) | CYP3A4SRCPDE9AFLT3PIK3CD | |
| SCHEMBL1128531 | 0.83 | CYP3A4 (0.66) | CYP3A4PIK3CDCYP2C9 | |
| SCHEMBL1128460 | 0.81 | CYP3A4 (0.49) | CYP3A4SRCPDE9AFLT3PIK3CD | |
| SCHEMBL1128256 | 0.81 | CYP3A4 (0.52) | CYP3A4PIK3CDCYP2C9 | |
| SCHEMBL1129104 | 0.81 | SMN1; SMN2 (0.43) | CYP3A4FLT3CYP2C9LCK | |
| Trifluoroacetic Acid SCHEMBL1128524 | 0.80 | CYP3A4 (0.68) | CYP3A4FLT3CYP2C9 | |
| SCHEMBL1128550 | 0.79 | CYP3A4 (0.51) | CYP3A4SRCPDE9AFLT3PIK3CD | |
| SCHEMBL1128747 | 0.78 | CYP3A4 (0.53) | CYP3A4FLT3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | CYP3A4 1503/4885SRC 2944/4885PDE9A 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.